Vimarsana
Biggest News Aggregation in the World

Iron Burden News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Iron Burden. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Iron Burden Today - Breaking & Trending Today

Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels - Vimarsana News

Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

SOMERVILLE, Mass.--(BUSINESS WIRE)--Dec 10, 2023--

Bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress - Vimarsana News

Bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

- Continued strong commercial launch for ZYNTEGLO® and SKYSONA®; 22 patient starts across both programs to date – - Ended quarter with $227M in cash, cash equivalents, marketable securities and...

bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress - Vimarsana News

bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

SOMERVILLE, Mass.--(BUSINESS WIRE)--Nov 7, 2023--

Bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition - Vimarsana News

Bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition

Oral presentation details efficacy, safety and health-related quality of life data in adult and pediatric patients with sickle cell disease treated with lovo-cel in HGB-206 Group C and HGB-210 ...